MiMedx Group, Inc. (MDXG) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.33%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.86%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.33% | Research and development expense / revenue. Period ending 2026-06-30. $15.38M ÷ $355.17M × 100 ≈ 4.33% |
| Stock-based compensation / revenue · 12 months | 1.86% | Share-based compensation / revenue. Period ending 2026-06-30. $6.59M ÷ $355.17M × 100 ≈ 1.86% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.38M USD | Research and Development Expense |
| Revenue | 355.17M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 6.59M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 8.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.38M | $355.17M | $6.59M | $8.75M | (m) | 4.33% | 1.86% | (m) | (m) |
| 2026-03-31 | $15.91M | $389.42M | $10.44M | $39.59M | (m) | 4.09% | 2.68% | (m) | (m) |
| 2025-12-31 | $15.10M | $418.63M | $16.40M | $63.89M | (m) | 3.61% | 3.92% | (m) | (m) |
| 2025-09-30 | $13.91M | $393.44M | $18.63M | $53.86M | (m) | 3.53% | 4.73% | (m) | (m) |
| 2025-06-30 | $13.12M | $363.77M | $17.52M | $42.84M | (m) | 3.61% | 4.82% | (m) | (m) |
| 2025-03-31 | $12.83M | $352.38M | $16.86M | $53.92M | (m) | 3.64% | 4.78% | (m) | (m) |
| 2024-12-31 | $12.34M | $348.88M | $16.93M | $58.87M | (m) | 3.54% | 4.85% | (m) | (m) |
| 2024-09-30 | $11.20M | $342.80M | $16.63M | $63.30M | (m) | 3.27% | 4.85% | (m) | (m) |
| 2024-06-30 | $11.36M | $340.46M | $17.20M | $63.26M | (m) | 3.34% | 5.05% | (m) | (m) |
| 2024-03-31 | $12.02M | $334.51M | $17.39M | $50.65M | (m) | 3.59% | 5.20% | (m) | (m) |
| 2023-12-31 | $12.66M | $321.48M | $16.96M | $37.12M | (m) | 3.94% | 5.28% | (m) | (m) |
| 2023-09-30 | $23.57M | $309.02M | $14.66M | $11.29M | (m) | 7.63% | 4.74% | (m) | (m) |
| 2023-06-30 | $26.35M | $295.00M | $12.64M | $-6.63M | (m) | 8.93% | 4.29% | (m) | (m) |
| 2023-03-31 | $23.36M | $280.62M | $13.01M | $-19.05M | (m) | 8.32% | 4.64% | (m) | (m) |
| 2022-12-31 | $22.83M | $267.84M | $12.67M | $-24.97M | (m) | 8.52% | 4.73% | (m) | (m) |
| 2022-09-30 | $22.00M | $260.88M | $14.44M | $-22.74M | (m) | 8.43% | 5.54% | (m) | (m) |
| 2022-06-30 | $20.42M | $256.26M | $15.88M | $-16.71M | (m) | 7.97% | 6.20% | (m) | (m) |
| 2022-03-31 | $18.97M | $257.54M | $15.51M | $-7.48M | (m) | 7.37% | 6.02% | (m) | (m) |
| 2021-12-31 | $17.34M | $258.62M | $14.76M | $-5.04M | (m) | 6.71% | 5.71% | (m) | (m) |
| 2021-09-30 | $16.20M | $259.75M | $15.02M | $-24.43M | (m) | 6.24% | 5.78% | (m) | (m) |
| 2021-06-30 | $15.21M | $260.98M | $14.88M | $-33.06M | (m) | 5.83% | 5.70% | (m) | (m) |
| 2021-03-31 | $13.40M | $246.47M | $15.25M | $-38.51M | (m) | 5.44% | 6.19% | (m) | (m) |
| 2020-12-31 | $11.71M | $248.23M | $15.36M | $-45.40M | (m) | 4.72% | 6.19% | (m) | (m) |
| 2020-09-30 | $11.00M | $256.09M | $14.32M | $-34.18M | (m) | 4.30% | 5.59% | (m) | (m) |
| 2020-06-30 | $10.32M | $280.65M | $13.33M | $-10.27M | (m) | 3.68% | 4.75% | (m) | (m) |
| 2020-03-31 | $10.89M | $294.44M | $12.40M | $-21.49M | (m) | 3.70% | 4.21% | (m) | (m) |
| 2019-12-31 | $11.14M | $299.25M | $12.06M | $-21.16M | (m) | 3.72% | 4.03% | (m) | (m) |
| 2019-09-30 | $12.96M | $315.44M | $10.66M | $-25.23M | (m) | 4.11% | 3.38% | (m) | (m) |
| 2019-06-30 | $14.23M | $313.54M | $11.93M | $-39.06M | (m) | 4.54% | 3.80% | (m) | (m) |
| 2019-03-31 | $15.12M | $341.52M | $12.85M | $-20.31M | (m) | 4.43% | 3.76% | (m) | (m) |
| 2018-12-31 | $15.77M | $359.11M | $14.77M | $-3.92M | (m) | 4.39% | 4.11% | (m) | (m) |
| 2018-09-30 | $14.70M | $354.38M | $19.27M | $29.00M | (m) | 4.15% | 5.44% | (m) | (m) |
| 2018-06-30 | $16.21M | $351.42M | $20.62M | $37.47M | (m) | 4.61% | 5.87% | (m) | (m) |
| 2018-03-31 | $17.24M | $336.49M | $21.45M | $43.01M | (m) | 5.12% | 6.38% | (m) | (m) |
| 2017-12-31 | $17.90M | $321.14M | $21.20M | $46.22M | (m) | 5.57% | 6.60% | (m) | (m) |
| 2017-09-30 | $17.89M | (m) | $19.22M | $30.96M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $15.32M | (m) | $18.62M | $26.82M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $13.74M | (m) | $17.87M | $23.16M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $12.04M | (m) | $17.82M | $18.45M | $339.00K | (m) | (m) | 54.41× | Reported |
| 2016-09-30 | $10.92M | (m) | $18.16M | $17.48M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $10.19M | (m) | $17.83M | $19.49M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $9.08M | (m) | $17.58M | $21.58M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $8.41M | (m) | $16.90M | $24.36M | $86.00K | (m) | (m) | 283.30× | Reported |
| 2015-09-30 | $7.92M | (m) | $15.86M | $21.27M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $7.75M | (m) | $14.50M | $18.28M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $7.49M | (m) | $13.01M | $12.24M | $41.00K | (m) | (m) | 298.49× | Reported |
| 2014-12-31 | $7.05M | (m) | $11.45M | $7.10M | $48.00K | (m) | (m) | 147.92× | Reported |
| 2014-09-30 | $6.59M | (m) | $10.01M | $1.04M | $51.31K | (m) | (m) | 20.20× | Reported |
| 2014-06-30 | $5.86M | (m) | $8.66M | $-2.95M | $46.71K | (m) | (m) | -63.16× | Reported |
| 2014-03-31 | $4.99M | (m) | $7.40M | $-3.30M | $51.45K | (m) | (m) | -64.19× | Reported |
| 2013-12-31 | $4.84M | (m) | $6.01M | $-2.64M | $45.23K | (m) | (m) | -58.33× | Reported |
| 2013-09-30 | $4.59M | (m) | $4.48M | $-2.20M | $174.20K | (m) | (m) | -12.62× | Reported |
| 2013-06-30 | $4.15M | (m) | $3.48M | $-5.58M | $315.25K | (m) | (m) | -17.69× | Reported |
| 2013-03-31 | $3.72M | (m) | $2.56M | $-4.95M | $455.89K | (m) | (m) | -10.86× | Reported |
| 2012-12-31 | $2.88M | (m) | $2.08M | $-5.36M | $592.89K | (m) | (m) | -9.03× | Reported |
| 2012-09-30 | $2.04M | (m) | $1.71M | $-6.82M | $806.72K | (m) | (m) | -8.45× | Reported |
| 2012-06-30 | $1.76M | (m) | $1.38M | $-4.84M | $693.82K | (m) | (m) | -6.97× | Reported |
| 2012-03-31 | $2.05M | (m) | $1.33M | $-7.14M | $585.34K | (m) | (m) | -12.19× | Reported |
| 2011-12-31 | $2.60M | $7.76M | $1.31M | $-9.76M | $432.97K | 33.54% | 16.85% | -22.54× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $2.75M | $788.87K | $996.31K | $-10.53M | $599.65K | 349.02% | 126.29% | -17.56× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B |